Literature DB >> 23087180

Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis.

Simon J Freeley1, Alice M Coughlan, Reena J Popat, Deborah K Dunn-Walters, Michael G Robson.   

Abstract

OBJECTIVES: Granulocyte colony stimulating factor (GCSF) is important in mobilising neutrophils from the bone marrow but also has a range of proinflammatory effects. We therefore decided to investigate the role of GCSF in antineutrophil cytoplasmic antibody (ANCA) vasculitis.
METHODS: We measured GCSF levels in the serum of 38 patients with active ANCA vasculitis compared with 31 age-matched controls, and assessed the effect of GCSF priming on the response of human neutrophils to ANCA. We also examined the effect of exogenous GCSF administration in a murine model of antimyeloperoxidase (anti-MPO) vasculitis, and the effect of GCSF on murine neutrophil activation.
RESULTS: The serum levels of GCSF in patients with active ANCA vasculitis were significantly higher than those of age matched healthy controls (mean 38.04 vs 18.35 pg/ml, p<0.001). Furthermore, we demonstrated that GCSF primed human neutrophils in vitro for a respiratory burst in response to anti-MPO ANCA. In an anti-MPO antibody transfer model, mice given GCSF had more crescents (mean 29.1% vs 5.8% per glomerular cross section, p<0.05), more macrophages (mean 3.2 vs 1.2 per glomerular cross-section, p<0.01), higher serum creatines (mean 13.6 vs 8.3 μmol/l, p<0.05) and more haematuria (p<0.05) compared with controls. In vivo administration of GCSF with lipopolysaccharide (LPS), but not LPS alone, led to upregulation of CD11c on murine neutrophils.
CONCLUSIONS: These data suggest that GCSF, which is raised in patient serum, may play an important role in exacerbating disease in ANCA vasculitis. In addition, GCSF therapy for neutropenia should be used with caution in these patients.

Entities:  

Keywords:  Autoantibodies; Autoimmune Diseases; Inflammation

Mesh:

Substances:

Year:  2012        PMID: 23087180     DOI: 10.1136/annrheumdis-2012-202160

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   27.973


  10 in total

Review 1.  Re-Examining Neutrophil Participation in GN.

Authors:  Dawn J Caster; David W Powell; Irina Miralda; Richard A Ward; Kenneth R McLeish
Journal:  J Am Soc Nephrol       Date:  2017-06-15       Impact factor: 10.121

Review 2.  The role of neutrophils and NETosis in autoimmune and renal diseases.

Authors:  Sarthak Gupta; Mariana J Kaplan
Journal:  Nat Rev Nephrol       Date:  2016-05-31       Impact factor: 28.314

Review 3.  An update on drug-induced arthritis.

Authors:  Marwan H Adwan
Journal:  Rheumatol Int       Date:  2016-03-21       Impact factor: 2.631

4.  Coaxing Anti-Inflammatory Granulocytes to Prevent Ischemic Kidney Injury: A Fine Balance.

Authors:  Alan D Salama; Mark A Little
Journal:  J Am Soc Nephrol       Date:  2020-03-04       Impact factor: 10.121

5.  Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis.

Authors:  Arnaud Millet; Katherine R Martin; Francis Bonnefoy; Philippe Saas; Julie Mocek; Manal Alkan; Benjamin Terrier; Anja Kerstein; Nicola Tamassia; Senthil Kumaran Satyanarayanan; Amiram Ariel; Jean-Antoine Ribeil; Loïc Guillevin; Marco A Cassatella; Antje Mueller; Nathalie Thieblemont; Peter Lamprecht; Luc Mouthon; Sylvain Perruche; Véronique Witko-Sarsat
Journal:  J Clin Invest       Date:  2015-10-05       Impact factor: 14.808

6.  Filgrastim-Induced Crescentic Transformation of Recurrent IgG2λ GN.

Authors:  Ibrahim Batal; Glen S Markowitz; Waichi Wong; Rupali Avasare; Markus Y Mapara; Gerald B Appel; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2016-05-04       Impact factor: 10.121

7.  G-CSF-induced ANCA associated glomerulonephritis in the presence of silent membranous "full house nephropathy" in an altruistic bone marrow donor.

Authors:  Avital Angel Korman; Adi Leiba; Yonatan Edel; Vladimir Rapoport; Ana Tobar; Merav Leiba
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

8.  Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies.

Authors:  Aisling Ui Mhaonaigh; Alice M Coughlan; Amrita Dwivedi; Jack Hartnett; Joana Cabral; Barry Moran; Kiva Brennan; Sarah L Doyle; Katherine Hughes; Rosemary Lucey; Achilleas Floudas; Ursula Fearon; Susan McGrath; Sarah Cormican; Aine De Bhailis; Eleanor J Molloy; Gareth Brady; Mark A Little
Journal:  Front Immunol       Date:  2019-11-07       Impact factor: 7.561

Review 9.  Immunopathogenesis of ANCA-Associated Vasculitis.

Authors:  Andreas Kronbichler; Keum Hwa Lee; Sara Denicolò; Daeun Choi; Hyojeong Lee; Donghyun Ahn; Kang Hyun Kim; Ji Han Lee; HyungTae Kim; Minha Hwang; Sun Wook Jung; Changjun Lee; Hojune Lee; Haejune Sung; Dongkyu Lee; Jaehyuk Hwang; Sohee Kim; Injae Hwang; Do Young Kim; Hyung Jun Kim; Geonjae Cho; Yunryoung Cho; Dongil Kim; Minje Choi; Junhye Park; Junseong Park; Kalthoum Tizaoui; Han Li; Lee Smith; Ai Koyanagi; Louis Jacob; Philipp Gauckler; Jae Il Shin
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

10.  Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.

Authors:  Simon J Freeley; Reena J Popat; Kiran Parmar; Martin Kolev; Beverley J Hunt; Cordula M Stover; Willhelm Schwaeble; Claudia Kemper; Michael G Robson
Journal:  J Pathol       Date:  2016-09       Impact factor: 9.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.